Concepts (176)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Angelman Syndrome | 18 | 2022 | 140 | 6.020 |
Why?
|
| Seizures | 16 | 2023 | 2917 | 1.940 |
Why?
|
| Anticonvulsants | 13 | 2023 | 1879 | 1.500 |
Why?
|
| Epilepsies, Myoclonic | 3 | 2018 | 85 | 1.230 |
Why?
|
| Trisomy | 3 | 2015 | 260 | 0.960 |
Why?
|
| Chromosomes, Human, Pair 15 | 8 | 2020 | 363 | 0.850 |
Why?
|
| Glycemic Index | 2 | 2017 | 396 | 0.810 |
Why?
|
| Spasms, Infantile | 2 | 2023 | 296 | 0.790 |
Why?
|
| Electroencephalography | 15 | 2022 | 6189 | 0.740 |
Why?
|
| GABA Agonists | 1 | 2020 | 105 | 0.720 |
Why?
|
| Epilepsy | 12 | 2019 | 3267 | 0.670 |
Why?
|
| Isoxazoles | 1 | 2020 | 230 | 0.650 |
Why?
|
| Gastrointestinal Diseases | 2 | 2017 | 1189 | 0.580 |
Why?
|
| Diazepam | 1 | 2018 | 215 | 0.570 |
Why?
|
| Phenylalanine-tRNA Ligase | 1 | 2016 | 15 | 0.540 |
Why?
|
| Meningoencephalitis | 1 | 2014 | 83 | 0.460 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2018 | 893 | 0.430 |
Why?
|
| Status Epilepticus | 1 | 2018 | 456 | 0.410 |
Why?
|
| Hospitals, General | 1 | 2016 | 795 | 0.390 |
Why?
|
| Encephalitis | 1 | 2014 | 437 | 0.370 |
Why?
|
| Child, Preschool | 22 | 2021 | 42056 | 0.360 |
Why?
|
| Mitochondrial Proteins | 1 | 2016 | 979 | 0.350 |
Why?
|
| Autoantibodies | 1 | 2018 | 2119 | 0.340 |
Why?
|
| Diet, Carbohydrate-Restricted | 1 | 2012 | 261 | 0.330 |
Why?
|
| Heterozygote | 1 | 2016 | 2798 | 0.330 |
Why?
|
| Hernia | 1 | 2008 | 68 | 0.310 |
Why?
|
| Delta Rhythm | 2 | 2021 | 81 | 0.310 |
Why?
|
| Frontal Lobe | 1 | 2014 | 1420 | 0.300 |
Why?
|
| Anxiety | 3 | 2021 | 4538 | 0.290 |
Why?
|
| Ambulatory Care | 1 | 2018 | 2782 | 0.280 |
Why?
|
| Child | 25 | 2023 | 79799 | 0.270 |
Why?
|
| Adolescent | 23 | 2021 | 87809 | 0.270 |
Why?
|
| Syndrome | 3 | 2022 | 3280 | 0.250 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2008 | 485 | 0.250 |
Why?
|
| Infant | 13 | 2023 | 36053 | 0.250 |
Why?
|
| Data Collection | 1 | 2014 | 3315 | 0.240 |
Why?
|
| Massachusetts | 4 | 2018 | 8803 | 0.230 |
Why?
|
| Constipation | 2 | 2018 | 561 | 0.200 |
Why?
|
| Treatment Outcome | 9 | 2023 | 64981 | 0.190 |
Why?
|
| Ambulatory Care Facilities | 2 | 2018 | 926 | 0.180 |
Why?
|
| Male | 33 | 2021 | 359718 | 0.180 |
Why?
|
| Young Adult | 12 | 2021 | 58748 | 0.180 |
Why?
|
| Mutation | 7 | 2019 | 29957 | 0.180 |
Why?
|
| Sleep | 1 | 2016 | 4750 | 0.170 |
Why?
|
| Brain | 6 | 2019 | 26951 | 0.170 |
Why?
|
| Fumarate Hydratase | 1 | 2019 | 52 | 0.170 |
Why?
|
| Brain Diseases | 1 | 2008 | 1540 | 0.170 |
Why?
|
| Chromosome Duplication | 2 | 2019 | 75 | 0.160 |
Why?
|
| Female | 32 | 2021 | 391246 | 0.160 |
Why?
|
| Hyperventilation | 1 | 2019 | 79 | 0.160 |
Why?
|
| Psychomotor Disorders | 1 | 2019 | 149 | 0.160 |
Why?
|
| Humans | 44 | 2023 | 760613 | 0.160 |
Why?
|
| Buspirone | 1 | 2019 | 81 | 0.160 |
Why?
|
| Muscle Hypotonia | 1 | 2019 | 160 | 0.150 |
Why?
|
| Piracetam | 2 | 2009 | 88 | 0.150 |
Why?
|
| Retrospective Studies | 13 | 2018 | 80345 | 0.150 |
Why?
|
| Drug Administration Schedule | 2 | 2020 | 4899 | 0.150 |
Why?
|
| Chromosome Aberrations | 4 | 2019 | 1767 | 0.150 |
Why?
|
| Double-Blind Method | 2 | 2023 | 12427 | 0.150 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2019 | 285 | 0.150 |
Why?
|
| Ubiquitin-Protein Ligases | 5 | 2021 | 1888 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2018 | 36286 | 0.140 |
Why?
|
| Adult | 16 | 2023 | 220007 | 0.140 |
Why?
|
| Facies | 2 | 2019 | 223 | 0.140 |
Why?
|
| Blood Chemical Analysis | 1 | 2018 | 437 | 0.140 |
Why?
|
| Phenotype | 6 | 2022 | 16548 | 0.140 |
Why?
|
| Electrodiagnosis | 1 | 2016 | 148 | 0.130 |
Why?
|
| Senna Extract | 1 | 2015 | 3 | 0.130 |
Why?
|
| KCNQ2 Potassium Channel | 1 | 2015 | 19 | 0.130 |
Why?
|
| Bisacodyl | 1 | 2015 | 12 | 0.120 |
Why?
|
| Vomiting | 1 | 2018 | 650 | 0.120 |
Why?
|
| Uniparental Disomy | 1 | 2014 | 45 | 0.120 |
Why?
|
| Dysarthria | 1 | 2014 | 58 | 0.120 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2016 | 3765 | 0.120 |
Why?
|
| Enema | 1 | 2015 | 141 | 0.120 |
Why?
|
| Tuberous Sclerosis | 2 | 2013 | 1030 | 0.110 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2018 | 664 | 0.110 |
Why?
|
| Puerto Rico | 1 | 2014 | 373 | 0.110 |
Why?
|
| Autistic Disorder | 2 | 2013 | 1214 | 0.110 |
Why?
|
| Diagnosis, Differential | 3 | 2019 | 12968 | 0.110 |
Why?
|
| Chromosome Disorders | 1 | 2016 | 499 | 0.110 |
Why?
|
| Chromosomes | 1 | 2016 | 575 | 0.110 |
Why?
|
| DNA Copy Number Variations | 2 | 2019 | 2013 | 0.110 |
Why?
|
| Disease Management | 3 | 2019 | 2514 | 0.110 |
Why?
|
| Drug Therapy, Combination | 1 | 2023 | 6498 | 0.100 |
Why?
|
| Biopolymers | 1 | 2013 | 184 | 0.100 |
Why?
|
| Ocular Motility Disorders | 1 | 2014 | 143 | 0.100 |
Why?
|
| Malformations of Cortical Development | 1 | 2014 | 177 | 0.100 |
Why?
|
| Age Distribution | 1 | 2018 | 2893 | 0.100 |
Why?
|
| Ataxia | 1 | 2014 | 305 | 0.100 |
Why?
|
| Scoliosis | 1 | 2018 | 735 | 0.100 |
Why?
|
| Valproic Acid | 2 | 2016 | 441 | 0.090 |
Why?
|
| Fatal Outcome | 1 | 2016 | 1832 | 0.090 |
Why?
|
| Gastroesophageal Reflux | 1 | 2018 | 816 | 0.090 |
Why?
|
| Cohort Studies | 6 | 2019 | 41337 | 0.090 |
Why?
|
| Prevalence | 2 | 2018 | 15686 | 0.090 |
Why?
|
| Social Adjustment | 1 | 2012 | 632 | 0.090 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2014 | 378 | 0.090 |
Why?
|
| Microcephaly | 1 | 2014 | 425 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2020 | 10826 | 0.090 |
Why?
|
| Health Surveys | 2 | 2018 | 4063 | 0.080 |
Why?
|
| Pilot Projects | 1 | 2023 | 8556 | 0.080 |
Why?
|
| Canada | 1 | 2014 | 2126 | 0.080 |
Why?
|
| Immunologic Factors | 1 | 2018 | 1588 | 0.080 |
Why?
|
| Clonazepam | 1 | 2009 | 133 | 0.080 |
Why?
|
| Polyethylene Glycols | 1 | 2015 | 1189 | 0.080 |
Why?
|
| Intelligence | 1 | 2012 | 919 | 0.070 |
Why?
|
| Parent-Child Relations | 1 | 2012 | 758 | 0.070 |
Why?
|
| Child Behavior Disorders | 1 | 2012 | 805 | 0.070 |
Why?
|
| Triazines | 1 | 2009 | 310 | 0.070 |
Why?
|
| Bhutan | 2 | 2017 | 62 | 0.070 |
Why?
|
| Epilepsy, Generalized | 1 | 2009 | 178 | 0.070 |
Why?
|
| Drug Prescriptions | 1 | 2016 | 1673 | 0.070 |
Why?
|
| Drug Tolerance | 1 | 2008 | 369 | 0.070 |
Why?
|
| Evaluation Studies as Topic | 1 | 2008 | 1628 | 0.070 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2009 | 224 | 0.060 |
Why?
|
| Activities of Daily Living | 1 | 2014 | 2417 | 0.060 |
Why?
|
| Cognition | 1 | 2021 | 6964 | 0.060 |
Why?
|
| Cerebral Angiography | 1 | 2008 | 1274 | 0.050 |
Why?
|
| Drug Resistance | 1 | 2009 | 1617 | 0.050 |
Why?
|
| Prognosis | 3 | 2017 | 29661 | 0.050 |
Why?
|
| Hippocampus | 1 | 2014 | 3738 | 0.050 |
Why?
|
| Cerebral Cortex | 1 | 2016 | 5761 | 0.040 |
Why?
|
| Myocardium | 1 | 2013 | 4700 | 0.040 |
Why?
|
| Quality of Life | 2 | 2018 | 13308 | 0.040 |
Why?
|
| Middle Aged | 5 | 2020 | 220359 | 0.040 |
Why?
|
| Receptor, Serotonin, 5-HT1A | 1 | 2019 | 55 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2014 | 8022 | 0.040 |
Why?
|
| Genomic Imprinting | 1 | 2020 | 330 | 0.040 |
Why?
|
| Infant, Newborn | 3 | 2019 | 26179 | 0.040 |
Why?
|
| Standard of Care | 1 | 2022 | 552 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2012 | 6379 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 39262 | 0.040 |
Why?
|
| Comorbidity | 2 | 2009 | 10553 | 0.040 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2021 | 6015 | 0.040 |
Why?
|
| Pediatrics | 1 | 2012 | 3586 | 0.030 |
Why?
|
| Phenytoin | 1 | 2016 | 188 | 0.030 |
Why?
|
| Carbamazepine | 1 | 2016 | 224 | 0.030 |
Why?
|
| Serotonin | 1 | 2019 | 1040 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2018 | 788 | 0.030 |
Why?
|
| Genotype | 2 | 2020 | 12957 | 0.030 |
Why?
|
| Cognition Disorders | 2 | 2018 | 3976 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2017 | 54306 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 1792 | 0.020 |
Why?
|
| Gene Duplication | 1 | 2013 | 314 | 0.020 |
Why?
|
| Body Fat Distribution | 1 | 2013 | 243 | 0.020 |
Why?
|
| Pedigree | 1 | 2019 | 4578 | 0.020 |
Why?
|
| Disease Progression | 1 | 2008 | 13505 | 0.020 |
Why?
|
| Angiomyolipoma | 1 | 2013 | 184 | 0.020 |
Why?
|
| Abdominal Neoplasms | 1 | 2013 | 286 | 0.020 |
Why?
|
| Movement Disorders | 1 | 2015 | 459 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2015 | 680 | 0.020 |
Why?
|
| Heart Neoplasms | 1 | 2013 | 360 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 2014 | 1387 | 0.020 |
Why?
|
| Epilepsy, Absence | 1 | 2009 | 49 | 0.020 |
Why?
|
| Caregivers | 1 | 2021 | 2224 | 0.020 |
Why?
|
| Online Systems | 1 | 2009 | 181 | 0.020 |
Why?
|
| Anxiety Disorders | 1 | 2019 | 2714 | 0.020 |
Why?
|
| Parents | 1 | 2021 | 3549 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2013 | 2505 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 8552 | 0.020 |
Why?
|
| United States | 1 | 2014 | 72448 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2008 | 1385 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2019 | 3531 | 0.020 |
Why?
|
| Epilepsies, Partial | 1 | 2009 | 430 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 15286 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2013 | 2802 | 0.010 |
Why?
|
| Severity of Illness Index | 2 | 2012 | 15840 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2010 | 4108 | 0.010 |
Why?
|
| Age Factors | 1 | 2019 | 18413 | 0.010 |
Why?
|
| Animals | 1 | 2013 | 167960 | 0.010 |
Why?
|
| Heart | 1 | 2013 | 4393 | 0.010 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2009 | 1079 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 20509 | 0.010 |
Why?
|
| Risk Factors | 1 | 2013 | 74333 | 0.000 |
Why?
|
| Aged | 1 | 2016 | 169143 | 0.000 |
Why?
|
Concepts
(176)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(37)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_